Tower Research Capital LLC (Trc) Arbutus Biopharma Corp Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 12,694 shares of ABUS stock, worth $57,376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,694
Previous 20,760
38.85%
Holding current value
$57,376
Previous $64,000
10.94%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding ABUS
# of Institutions
194Shares Held
118MCall Options Held
2.67MPut Options Held
693K-
Morgan Stanley New York, NY24.5MShares$111 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$60.3 Million22.38% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$52.2 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY11MShares$49.7 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.99MShares$40.6 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $678M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...